Cargando…
Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn’s disease
The advent of anti-tumor necrosis factor (TNF)-α therapy has been a major advance in the medical management of Crohn’s disease (CD). However, a significant proportion of patients with CD do not respond adequately to treatment with these agents. Primary and secondary nonresponse to anti-TNFα therapy...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4041179/ https://www.ncbi.nlm.nih.gov/pubmed/24904220 http://dx.doi.org/10.2147/CEG.S39518 |